COST

977.71

+1.05%↑

155.36

+1.42%↑

STZ

160.13

+2.92%↑

GIS

46.48

+1.91%↑

MKC

63.27

+3.65%↑

COST

977.71

+1.05%↑

155.36

+1.42%↑

STZ

160.13

+2.92%↑

GIS

46.48

+1.91%↑

MKC

63.27

+3.65%↑

COST

977.71

+1.05%↑

155.36

+1.42%↑

STZ

160.13

+2.92%↑

GIS

46.48

+1.91%↑

MKC

63.27

+3.65%↑

COST

977.71

+1.05%↑

155.36

+1.42%↑

STZ

160.13

+2.92%↑

GIS

46.48

+1.91%↑

MKC

63.27

+3.65%↑

COST

977.71

+1.05%↑

155.36

+1.42%↑

STZ

160.13

+2.92%↑

GIS

46.48

+1.91%↑

MKC

63.27

+3.65%↑

Home・Aktien・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Open

BrancheKonsumgüter defensiv

7.88 -8.37

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.85

Max

8.64

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.9M -10M
Verkäufe	-5.3M 31M
Gewinnspanne	-32.116
Angestellte	406

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	33M 274M
Vorheriger Eröffnungskurs	16.25
Vorheriger Schlusskurs	7.88

Nachrichtenstimmung

By Acuity

50%

64 / 133 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Feb. 2026, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2. Feb. 2026, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2. Feb. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2. Feb. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2. Feb. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2. Feb. 2026, 23:23 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2. Feb. 2026, 22:57 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2. Feb. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2. Feb. 2026, 21:51 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Feb. 2026, 21:49 UTC

Ergebnisse

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2. Feb. 2026, 21:39 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:36 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2. Feb. 2026, 21:34 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2. Feb. 2026, 21:23 UTC

Ergebnisse

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2. Feb. 2026, 21:19 UTC

Ergebnisse

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2. Feb. 2026, 21:17 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2. Feb. 2026, 21:17 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:10 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:08 UTC

Ergebnisse

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2. Feb. 2026, 21:07 UTC

Ergebnisse

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Net $608.7M >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Rev $1.41B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Adj EPS 25c >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q EPS 24c >PLTR

2. Feb. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer-Vergleich

Kursveränderung

Lifecore Biomedical Inc Prognose

Rating-Konsens

By TipRanks

Buy

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lifecore Biomedical Inc – Dist abgegeben haben.

Stimmung

By Acuity

64 / 133 Ranking in Konsumgüter defensiv

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.